Traitement par éplérénone dans la choriorétinite séreuse centrale chronique

Sampo, M.; Soler, V.; Gascon, Pierre; Yin, G. Ho Wang; Hoffart, L.; Denis, D.; Matonti, F.

doi:10.1016/j.jfo.2016.01.008

Cited by 14 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no significant difference between the two dosages, although it should be noted that the follow-up of the studies is short-term and no randomized study has compared the two treatment regimens [ 35 – 37 ]. In addition, the majority of studies were retrospective with limited number of patients [ 14 , 26 – 34 ]. Sampo et al conducted a retrospective study with the largest study sample of 27 patients with chronic CSCR and demonstrated statistically significant anatomical and functional improvement in such patients at the 3-month follow-up [ 34 ].…”

Section: Literature Searchmentioning

confidence: 99%

“…In addition, the majority of studies were retrospective with limited number of patients [ 14 , 26 – 34 ]. Sampo et al conducted a retrospective study with the largest study sample of 27 patients with chronic CSCR and demonstrated statistically significant anatomical and functional improvement in such patients at the 3-month follow-up [ 34 ]. Prospective studies have shown similar results [ 25 , 35 – 38 ].…”

Section: Literature Searchmentioning

confidence: 99%

See 1 more Smart Citation

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

et al. 2018

View full text Add to dashboard Cite

PurposeThe purpose of this review is to examine the role of eplerenone in the treatment of central serous chorioretinopathy (CSCR).MethodsA comprehensive search of the PubMed database has been conducted regarding eplerenone for CSCR, while studies using spironolactone were excluded. Articles and book chapters cited in the reference lists of articles obtained by this method were reviewed and included when considered appropriate, while the retrieved articles were filtered manually to exclude duplicates.ResultsOral eplerenone at a dose of 25–50 mg/day has been found to be effective and well-tolerated for the treatment of chronic CSCR. The published studies have shown significant improvement in visual acuity and decrease or total absorption of subretinal fluid in patients with CSCR treated with oral eplerenone. However, it should be noted that the majority of studies were retrospective with limited number of patients and short follow-up. On the other hand, patients presenting widespread retinal pigment epithelium changes are less likely to benefit from eplerenone treatment, which may argue for an earlier intervention.ConclusionsCSCR is a challenging disease to understand and treat, since its pathogenesis remains elusive and multifactorial. Pharmacologic approaches, like eplerenone, are intriguing, as they target several pathophysiological pathways and may lead to visual acuity improvement and more rapid recovery.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Section: Literature Searchmentioning

confidence: 99%

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Most studies were retrospective. Largest of these studies was by Sampo et al16 who included 27 patients and Gergely et al17 who studied 28 cases with 3 and 6 months follow-up respectively.…”

Section: Discussionmentioning

confidence: 99%

Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy

Farooq¹,

Habib²,

Shah

et al. 2019

Pak J Med Sci

View full text Add to dashboard Cite

Objective:To determine the efficacy of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy (CSCR).Methods:This quasi experimental study was performed at PNS Shifa Hospital Karachi from September 2018 to February 2019. Study included 23 patients. Patients were included using consecutive sampling technique and informed consent was taken from all patients before staring treatment. 50 mg of oral eplerenone per day was given for three months. Subretinal fluid (SRF) height and visual acuity (VA) were noted at baseline, one month and three month follow-up. Structured Study performa was used for data collection. Data was analysed and assessed with SPSS version 23. P value of <0.05 was considered statistically significant.Results:Mean age of patients was 40.7±7 years and mean duration of disease before treatment was 3.7±0.76 months. Mean baseline BCVA and SRF height was 0.39±0.02 logMAR and 123±12.5 µm respectively. Sixty-five percent patients responded at one month and 80% at three months with reduction in SRF height. Improvement in visual acuity was also statistically significant at 3 months (p<0.05).Conclusion:Use of eplerenone in chronic CSCR resulted in significant improvement in vision and decrease in mean SRF height.

show abstract

“…Owing to the excellent selectivity, eplerenone is being evaluated as a promising therapeutic agent in the management of chronic CSC in various studies. [ 48 49 ] In a randomized, double-blind, placebo-controlled pilot study including 15 patients, oral eplerenone was given as 25 mg daily for 1 week followed by 50 mg daily for 8 weeks in cases of chronic CSC. The therapy was found safe and potentially effective, resulting in improvement in maximum SRF height, maximum subfoveal fluid height, central subfield thickness, and BCVA.…”

Section: Medical Managementmentioning

confidence: 99%

Central serous chorioretinopathy: Current update on management

et al. 2018

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC), the fourth most common nonsurgical retinopathy with a usual self-limiting course, is known to present with persistent or recurrent form with distressing visual loss. Evolution of newer mutimodal imaging techniques have revolutionized the understanding about the pathophysiology of CSC, and hence the diagnosis and management. Multifactorial etiopathology of CSC promotes the use of multiple treatment modalities. With advances in investigative options, treatment options including conventional focal laser, micropulse laser, photodynamic therapy, and transpupillary thermotherapy are also advancing and refining. Medical management for CSC is also under evaluation with a wide spectrum of new drugs in vogue. However, standard of treatment is yet to be established through randomized clinical trials. This review article discusses the current approach to multimodal treatment options for CSC including conventional as well as newer therapeutic modalities.

show abstract

Traitement par éplérénone dans la choriorétinite séreuse centrale chronique

Cited by 14 publications

References 21 publications

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature

Effect of oral eplerenone in anatomical and functional improvement in patients with chronic central serous chorioretinopathy

Central serous chorioretinopathy: Current update on management

Contact Info

Product

Resources

About